← Back to Search

Vaccine

mRNA-1020 for Flu

Phase 1 & 2
Waitlist Available
Research Sponsored by ModernaTX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 8 and 181
Awards & highlights

Study Summary

This trial is testing the safety and effectiveness of three different vaccines against the flu.

Eligible Conditions
  • Flu

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 8 and 181
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 8 and 181 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
GMFR of Anti-NA Antibodies at Day 29 as Measured by NAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
GMT of Anti-Neuraminidase (NA) Antibodies at Day 29 as Measured by Neuraminidase Inhibition (NAI) Assay for Vaccine-Matched Seasonal Influenza A and B Strains
Geometric Mean Fold-Rise (GMFR) of Anti-HA Antibodies at Day 29 as Measured by HAI Assay Vaccine-Matched Seasonal Influenza A and B Strains
+6 more
Secondary outcome measures
GMFR of Anti-HA or Anti-NA Antibodies at Days 8 and 181 as Measured by HAI and NAI Assays for Vaccine-Matched Seasonal Influenza A and B Strains
GMT of Anti-HA or Anti-NA Antibodies at Days 8 and 181 as Measured by HAI and NAI Assays for Vaccine-Matched Seasonal Influenza A and B Strains

Side effects data

From 2022 Phase 1 & 2 trial • 572 Patients • NCT05333289
49%
Injection site pain
25%
Fatigue
23%
Headache
20%
Arthralgia
15%
Myalgia
14%
Injection site lymphadenopathy
11%
Chills
10%
Vomiting
7%
COVID-19
4%
Rhinovirus infection
3%
Oropharyngeal pain
3%
Injection site erythema
3%
Injection site induration
3%
Upper respiratory tract infection
1%
Sinusitis
1%
Cough
1%
Splenic rupture
1%
Accidental overdose
1%
Haemoglobin decreased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Flublok
mRNA-1020 Dose Level A
mRNA-1010
mRNA-1030 Dose Level A
mRNA-1030 Dose Level B
mRNA-1020 Dose Level B
mRNA-1030 Dose Level C
mRNA-1020 Dose Level C

Trial Design

8Treatment groups
Experimental Treatment
Active Control
Group I: mRNA-1030 Dose Level CExperimental Treatment1 Intervention
Participants will receive mRNA-1030 at Dose Level C by IM injection on Day 1.
Group II: mRNA-1030 Dose Level BExperimental Treatment1 Intervention
Participants will receive mRNA-1030 at Dose Level B by IM injection on Day 1.
Group III: mRNA-1030 Dose Level AExperimental Treatment1 Intervention
Participants will receive mRNA-1030 at Dose Level A by intramuscular (IM) injection on Day 1.
Group IV: mRNA-1020 Dose Level CExperimental Treatment1 Intervention
Participants will receive mRNA-1020 at Dose Level C by IM injection on Day 1.
Group V: mRNA-1020 Dose Level BExperimental Treatment1 Intervention
Participants will receive mRNA-1020 at Dose Level B by IM injection on Day 1.
Group VI: mRNA-1020 Dose Level AExperimental Treatment1 Intervention
Participants will receive mRNA-1020 at Dose Level A by IM injection on Day 1.
Group VII: Active ComparatorActive Control1 Intervention
Participants will receive an active comparator by IM injection on Day 1.
Group VIII: mRNA-1010Active Control1 Intervention
Participants will receive mRNA-1010 by IM injection on Day 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
mRNA-1030
2022
Completed Phase 2
~580
mRNA-1020
2022
Completed Phase 2
~580

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

ModernaTX, Inc.Lead Sponsor
108 Previous Clinical Trials
61,378,745 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
2022. "A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05333289.
~191 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top